These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32758887)
1. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Yaqinuddin A Med Hypotheses; 2020 Nov; 144():110049. PubMed ID: 32758887 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. Ansariniya H; Seifati SM; Zaker E; Zare F Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683 [TBL] [Abstract][Full Text] [Related]
3. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Liu WJ; Zhao M; Liu K; Xu K; Wong G; Tan W; Gao GF Antiviral Res; 2017 Jan; 137():82-92. PubMed ID: 27840203 [TBL] [Abstract][Full Text] [Related]
4. Limited Recognition of Highly Conserved Regions of SARS-CoV-2. Swaminathan S; Lineburg KE; Ambalathingal GR; Crooks P; Grant EJ; Mohan SV; Raju J; Panikkar A; Le Texier L; Tong ZWM; Chew KY; Neller MA; Short KR; Gowda H; Gras S; Khanna R; Smith C Microbiol Spectr; 2022 Feb; 10(1):e0278021. PubMed ID: 35196796 [TBL] [Abstract][Full Text] [Related]
5. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. Bhattacharya M; Sharma AR; Patra P; Ghosh P; Sharma G; Patra BC; Lee SS; Chakraborty C J Med Virol; 2020 Jun; 92(6):618-631. PubMed ID: 32108359 [TBL] [Abstract][Full Text] [Related]
6. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM Front Immunol; 2020; 11():1979. PubMed ID: 32973803 [TBL] [Abstract][Full Text] [Related]
7. Human and novel coronavirus infections in children: a review. Rajapakse N; Dixit D Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines. De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679 [TBL] [Abstract][Full Text] [Related]
9. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray. Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808 [TBL] [Abstract][Full Text] [Related]
11. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century. Asrani P; Hasan GM; Sohal SS; Hassan MI OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting. Abdirizak F; Lewis R; Chowell G Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665 [TBL] [Abstract][Full Text] [Related]
13. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
14. Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. Labarrere CA; Kassab GS Front Immunol; 2021; 12():652252. PubMed ID: 34630377 [TBL] [Abstract][Full Text] [Related]
15. Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. O'Connell P; Aldhamen YA Hum Vaccin Immunother; 2020 Dec; 16(12):2980-2991. PubMed ID: 32878546 [TBL] [Abstract][Full Text] [Related]
17. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
18. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. Kumar V Int Rev Immunol; 2021; 40(1-2):5-53. PubMed ID: 32744465 [TBL] [Abstract][Full Text] [Related]
19. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Wooding DJ; Bach H Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241 [TBL] [Abstract][Full Text] [Related]
20. A Comparison of the Clinical, Viral, Pathologic, and Immunologic Features of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus 2019 (COVID-19) Diseases. Barth RF; Buja LM; Barth AL; Carpenter DE; Parwani AV Arch Pathol Lab Med; 2021 Oct; 145(10):1194-1211. PubMed ID: 34232978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]